Legend Announces FDA clearance of IND application on CAR-T immuno-cell therapy for the Treatment of Multiple Myeloma

Legend Announces FDA clearance of IND application on CAR-T immuno-cell therapy for the Treatment of Multiple Myeloma

LCAR-B38M CAR-T therapy (JNJ-68284528) to be developed as part of strategic partnership between Legend and Janssen PISCATAWAY, N.J., May 30, 2018 /PRNewswire/ — Legend Biotech, a subsidiary of GenScript Biotech Corporation (HKEx: 1548), announced today that the U.S. Food and Drug Administration